General Information of Drug (ID: DM0BT41)

Drug Name
NYX-458
Synonyms
Nevadistinel; YYL9TO6TW2; NEVADISTINEL [USAN]; SCHEMBL19850602; NYX-458; NYX-3054; HY-156626; CS-0886462; (4S)-2-[(4-Methoxyphenyl)methyl]-2,7-diazaspiro[3.5]nonane-1,6-dione; 2,7-Diazaspiro[3.5]nonane-1,6-dione, 2-[(4-methoxyphenyl)methyl]-, (4S)-; 2181816-92-0
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C15H18N2O3
Canonical SMILES
COC1=CC=C(C=C1)CN2CC3(C2=O)CCNC(=O)C3
InChI
InChI=1S/C15H18N2O3/c1-20-12-4-2-11(3-5-12)9-17-10-15(14(17)19)6-7-16-13(18)8-15/h2-5H,6-10H2,1H3,(H,16,18)/t15-/m0/s1
InChIKey
HMFZRGIXXDQHFG-HNNXBMFYSA-N
Cross-matching ID
PubChem CID
134241459
TTD ID
DB8V4Z

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04148391) A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia. U.S.National Institutes of Health.
2 NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. Mov Disord. 2020 Apr;35(4):640-649.